Floatz logo

Pembrolizumab

Urinary Bladder Cancer

Explore 23 assets in Urinary Bladder Cancer →
Floatz Rating
BB64/100
Confidence
Indicative
v0.2
Sponsor
Fred Hutchinson Cancer Center
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
49High confidence
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT05756569CT.gov
Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology
—Recruiting———
NCT04848519CT.gov
Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma
—Active Not Recruiting———
NCT04902040CT.gov
Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies
—Terminated———
NCT03589339CT.gov
NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy
—Active Not Recruiting———
NCT03582475CT.gov
Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate
—Active Not Recruiting———
NCT03229278CT.gov
Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma
—Completed———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Urinary Bladder Cancer

AssetSponsorPhaseRating
Pembrolizumab (this asset)Fred Hutchinson Cancer CenterP2BB · 64
Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4)Fred Hutchinson Cancer CenterP2BB
AtezolizumabNational Cancer Institute (NCI)P2BB
TrastuzumabIambic Therapeutics, IncP2BB
CarboplatinIambic Therapeutics, IncP2BB
NivolumabM.D. Anderson Cancer CenterP2B
AdriamycinM.D. Anderson Cancer CenterP2B
Cis-Diamminedichloroplatinum IiG1 Therapeutics, Inc.P2B
CabozantinibNational Cancer Institute (NCI)P2B

+37 more in the Urinary Bladder Cancer cohort

Other indications for Pembrolizumab

IndicationSponsorPhaseRating
Her2-Receptor Negative Breast Cancer—P2BBB · 72
Estrogen-Receptor Negative Breast Cancer—P2BB · 71
Progesterone-Receptor Negative Breast Cancer—P2BB · 71

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. Pembrolizumab in Urinary Bladder Cancer. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/pembrolizumab-urinary-bladder-cancer

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →